GENFIT : GENFIT-SANOFI Collaboration: Second Milestone achieved with success

 GENFIT : GENFIT-SANOFI Collaboration: Second Milestone achieved with success                           GENFIT-SANOFI Collaboration:                     Second Milestone achieved with success  Lille (France),  Boston (Massachusetts,  United States),  January 22,  2013  -  GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company  at  the forefront  of  drug  discovery  and development,  focusing  on  the  early  diagnosis  and  preventive   treatment  of   cardiometabolic  and   associated  disorders, today  announces  the  demonstration of  the  activity  of  several  chemical series,  selected as  part of  the second  approach of  its  research  program with SANOFI.  The achievement of this second key milestone follows on from the first one  in  April 2012, in the context of the research contract signed in March 2011 for a period of three years, during which SANOFI and GENFIT are committed to working together on the  discovery and  development of new  drug candidates  targeting  several metabolic disorders.  With this demonstration, a second  scientific foundation stone is thus  placed  for one of  the approaches  of this research  program targeting  mitochondrial  dysfunction. These results confirm the hypothesis, formulated in early 2011 on the basis of clinical observations, that the adaptation to stress of  cellular  mechanisms regulating  energy production  offers  a therapeutic  potential  in  numerous pathologies including metabolic diseases.    In accordance with  the terms  of the  contract, whereby  SANOFI obtained  the  exclusive worldwide rights to develop and commercialize the molecules  arising  from the  research  collaboration,  GENFIT  has received  the  second  of  the  milestone payments  included in  the  collaboration and  licensing  agreement.  Depending on  the preclinical  and clinical  development, and  the  subsequent  registration and commercialization  of resulting  products, the  total of  the  milestone payments included in  the agreement could  reach $54.5 million  (€39  million), in addition to royalties from future sales of products developed  by  SANOFI and resulting from the collaboration.  About GENFIT:  GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic  fields linked to cardiometabolic  disorders  (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases.). GENFIT uses  a multi-pronged  approach based  on early  diagnosis,  preventive  solutions,  and  therapeutic  treatments  and  advances  therapeutic  research  programs, either independently or  in partnership with leading  pharmaceutical  companies, including Sanofi, to address these major public health concerns and their unmet medical needs. GENFIT's research  programs  have resulted  in  the  creation of  a  rich  and  diversified pipeline of  drug candidates at  different stages of  development,  including GENFIT's lead  proprietary compound,  GFT505, that  is currently  in  PhaseIIb.  With facilities in  Lille, France, and  Cambridge, MA (USA),  the Company  has  approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext(TM)  Paris (Alternext: ALGFT; ISIN:  FR0004163111).  www.genfit.com  Contacts: GENFIT Jean-François Mouney - CEO & Chairman of the Management Board - Ph. +333 2016 4000 Milestones - Press Relations Bruno Arabian Ph. +331 7544 8740 / +336 8788 4726 - barabian@milestones.fr  2013.01.22 PR GENFIT-SANOFI.  ------------------------------------------------------------------------------  This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.  The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.  Source: GENFIT via Thomson Reuters ONE HUG#1671955  
Press spacebar to pause and continue. Press esc to stop.